ES2087616T3 - Fluoro-taxoles con actividad anti-tumoral. - Google Patents

Fluoro-taxoles con actividad anti-tumoral.

Info

Publication number
ES2087616T3
ES2087616T3 ES93110374T ES93110374T ES2087616T3 ES 2087616 T3 ES2087616 T3 ES 2087616T3 ES 93110374 T ES93110374 T ES 93110374T ES 93110374 T ES93110374 T ES 93110374T ES 2087616 T3 ES2087616 T3 ES 2087616T3
Authority
ES
Spain
Prior art keywords
alkyl
formula
taxoles
fluoro
alkynyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93110374T
Other languages
English (en)
Inventor
Shu-Hui Chen
Vittorio Farina
Dolatrai Vyas
Joydeep Kant
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/029,819 external-priority patent/US5254580A/en
Priority claimed from US08/062,687 external-priority patent/US5294637A/en
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ES2087616T3 publication Critical patent/ES2087616T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • H—ELECTRICITY
    • H05—ELECTRIC TECHNIQUES NOT OTHERWISE PROVIDED FOR
    • H05K—PRINTED CIRCUITS; CASINGS OR CONSTRUCTIONAL DETAILS OF ELECTRIC APPARATUS; MANUFACTURE OF ASSEMBLAGES OF ELECTRICAL COMPONENTS
    • H05K1/00—Printed circuits
    • H05K1/16—Printed circuits incorporating printed electric components, e.g. printed resistor, capacitor, inductor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/81—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/82—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/6551—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a four-membered ring
    • C07F9/65512—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a four-membered ring condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01L—SEMICONDUCTOR DEVICES NOT COVERED BY CLASS H10
    • H01L21/00—Processes or apparatus adapted for the manufacture or treatment of semiconductor or solid state devices or of parts thereof
    • H01L21/02—Manufacture or treatment of semiconductor devices or of parts thereof
    • H01L21/04—Manufacture or treatment of semiconductor devices or of parts thereof the devices having potential barriers, e.g. a PN junction, depletion layer or carrier concentration layer
    • H01L21/48—Manufacture or treatment of parts, e.g. containers, prior to assembly of the devices, using processes not provided for in a single one of the subgroups H01L21/06 - H01L21/326
    • H01L21/4814—Conductive parts
    • H01L21/4821—Flat leads, e.g. lead frames with or without insulating supports
    • H01L21/4839—Assembly of a flat lead with an insulating support, e.g. for TAB
    • H—ELECTRICITY
    • H05—ELECTRIC TECHNIQUES NOT OTHERWISE PROVIDED FOR
    • H05K—PRINTED CIRCUITS; CASINGS OR CONSTRUCTIONAL DETAILS OF ELECTRIC APPARATUS; MANUFACTURE OF ASSEMBLAGES OF ELECTRICAL COMPONENTS
    • H05K1/00—Printed circuits
    • H05K1/02—Details
    • H05K1/03—Use of materials for the substrate
    • H05K1/0306—Inorganic insulating substrates, e.g. ceramic, glass
    • H—ELECTRICITY
    • H05—ELECTRIC TECHNIQUES NOT OTHERWISE PROVIDED FOR
    • H05K—PRINTED CIRCUITS; CASINGS OR CONSTRUCTIONAL DETAILS OF ELECTRIC APPARATUS; MANUFACTURE OF ASSEMBLAGES OF ELECTRICAL COMPONENTS
    • H05K1/00—Printed circuits
    • H05K1/02—Details
    • H05K1/09—Use of materials for the conductive, e.g. metallic pattern
    • H05K1/092—Dispersed materials, e.g. conductive pastes or inks
    • H—ELECTRICITY
    • H05—ELECTRIC TECHNIQUES NOT OTHERWISE PROVIDED FOR
    • H05K—PRINTED CIRCUITS; CASINGS OR CONSTRUCTIONAL DETAILS OF ELECTRIC APPARATUS; MANUFACTURE OF ASSEMBLAGES OF ELECTRICAL COMPONENTS
    • H05K3/00—Apparatus or processes for manufacturing printed circuits
    • H05K3/40—Forming printed elements for providing electric connections to or between printed circuits
    • H05K3/403—Edge contacts; Windows or holes in the substrate having plural connections on the walls thereof

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microelectronics & Electronic Packaging (AREA)
  • General Physics & Mathematics (AREA)
  • Power Engineering (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Manufacturing & Machinery (AREA)
  • Computer Hardware Design (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Glass Compositions (AREA)
  • Catalysts (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

ESTA INVENCION SE REFIERE A UN TAXOL FLUORADO DE LA FORMULA I EN QUE R1 ES -CORZ EN QUE RZ ES RO 6, ALKENILO C2-6, ALKINILO C2-6, CICLOALKILO C3-6 O UN RADICAL DE LA FORMULA -W-RX EN QUE W ES UN ENLACE, ALKENODIILO C2-6 O -(CH2)T-, EN QUE T ES DE UNO A SEIS; Y RX ES NAFTILO, FURILO, TIENILO O FENILO Y ADEMAS RZ PUEDE SER OPCIONALMENTE SUSTITUIDO POR DE UNO A TRES DE LOS GRUPOS, IGUALES O DIFERENTES, ALKILO C1-6, ALCOXI C1-6, HALOGENO O -CF3; R2 ES -OCOR, H, OH, -OR, -OSO2R, OCONR (GRADOS) R, -COCNHR, -OCOO(CH2)TR O -OCOOR; Y R Y R (GRADOS) SON, INDEPENDIENTEMENTE, ALKILO C1-6, ALKENILO C2-6, CICLOALKILO C3-6, ALKINILO C2-6 O FENILO OPCIONALMENTE SUSTITUIDOS POR DE UNO A TRES DE LOS GRUPOS, IGUALES O DIFERENTES, ALKILO C1-6, ALCOXI C1-6, HALOGENO O -CF3. ADEMAS EN ESTA INVENCION SE PRESENTAN LAS FORMULACIONES FARMACEUTICAS Y LOS INTERMEDIOS UTILES PARA LOS TAXOLES FLUORADOS DE LA FORMULA I. TAMBIEN SE PRESENTA UN METODO PARA EL TRATAMIENTO DE TUMORES DE MAMIFEROS MEDIANTE EL USO DE UN COMPUESTO DE LA FORMULA I.
ES93110374T 1992-07-01 1993-06-29 Fluoro-taxoles con actividad anti-tumoral. Expired - Lifetime ES2087616T3 (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US90726192A 1992-07-01 1992-07-01
US99544392A 1992-12-23 1992-12-23
US99645592A 1992-12-24 1992-12-24
US642393A 1993-01-19 1993-01-19
US08/029,819 US5254580A (en) 1993-01-19 1993-03-11 7,8-cyclopropataxanes
US08/062,687 US5294637A (en) 1992-07-01 1993-05-20 Fluoro taxols

Publications (1)

Publication Number Publication Date
ES2087616T3 true ES2087616T3 (es) 1996-07-16

Family

ID=27555540

Family Applications (2)

Application Number Title Priority Date Filing Date
ES93110375T Expired - Lifetime ES2211861T3 (es) 1992-07-01 1993-06-29 7,8-ciclopropataxanos de accion antitumoral.
ES93110374T Expired - Lifetime ES2087616T3 (es) 1992-07-01 1993-06-29 Fluoro-taxoles con actividad anti-tumoral.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES93110375T Expired - Lifetime ES2211861T3 (es) 1992-07-01 1993-06-29 7,8-ciclopropataxanos de accion antitumoral.

Country Status (18)

Country Link
EP (2) EP0577082B1 (es)
JP (1) JP3261550B2 (es)
CN (1) CN1051309C (es)
AT (2) ATE136460T1 (es)
AU (1) AU656475B2 (es)
CY (1) CY1931A (es)
DE (2) DE69333339T2 (es)
DK (1) DK0577082T3 (es)
ES (2) ES2211861T3 (es)
FI (1) FI110942B (es)
GR (1) GR3019635T3 (es)
HK (1) HK155896A (es)
HU (1) HU220666B1 (es)
IL (1) IL106176A (es)
MX (1) MX9303900A (es)
NO (1) NO302520B1 (es)
NZ (1) NZ248017A (es)
PL (1) PL174374B1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6794523B2 (en) 1991-09-23 2004-09-21 Florida State University Taxanes having t-butoxycarbonyl substituted side-chains and pharmaceutical compositions containing them
US6005138A (en) 1991-09-23 1999-12-21 Florida State University Tricyclic taxanes having a butenyl substituted side-chain and pharmaceutical compositions containing them
US6521660B2 (en) 1991-09-23 2003-02-18 Florida State University 3′-alkyl substituted taxanes and pharmaceutical compositions containing them
MX9307777A (es) * 1992-12-15 1994-07-29 Upjohn Co 7-HALO-Y 7ß, 8ß-METANO-TAXOLES, USO ANTINEOPLASTICO Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN.
US5646176A (en) 1992-12-24 1997-07-08 Bristol-Myers Squibb Company Phosphonooxymethyl ethers of taxane derivatives
ATE249448T1 (de) * 1993-06-11 2003-09-15 Upjohn Co Delta 6,7-taxol derivate antineoplastische verbindungen und diese enthaltende pharmazeutische zusammenstellungen
IL127597A (en) * 1994-01-28 2003-07-31 Upjohn Co Iso-taxol analogs
FR2721023B1 (fr) * 1994-06-09 1996-07-12 Rhone Poulenc Rorer Sa Nouveaux Taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent.
FR2721024B1 (fr) * 1994-06-09 1996-07-12 Rhone Poulenc Rorer Sa Nouveaux taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent.
WO1996023779A1 (fr) * 1995-02-02 1996-08-08 Daiichi Pharmaceutical Co., Ltd. Derives ethers
IT1275936B1 (it) * 1995-03-17 1997-10-24 Indena Spa Derivati della 10-deacetilbaccatina iii e della 10-deacetil-14b- idrossibaccatina iii loro metodo di preparazione e formulazioni
FR2732342B1 (fr) * 1995-04-03 1997-04-30 Rhone Poulenc Rorer Sa Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
TW480262B (en) * 1995-04-28 2002-03-21 Daiichi Seiyaku Co A taxol derivative having an antitumor activity and a pharmaceutical composition comprising the same
EP1913958B1 (en) * 2006-08-03 2009-12-23 Sanofi-Aventis Antitumor compositions containing acetylcyclopropyl docetaxel and trastuzumab
CN101863861A (zh) * 2009-04-16 2010-10-20 山东靶点药物研究有限公司 一种简便高效地制备紫杉醇类似物Larotaxel的方法
US8791279B2 (en) * 2010-12-13 2014-07-29 Yung Shin Pharm. Ind. Co., Ltd. Process for preparing taxoids from baccatin derivatives using lewis acid catalyst

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0642503B1 (en) * 1991-09-23 1999-12-01 Florida State University 10-desacetoxytaxol derivatives

Also Published As

Publication number Publication date
CN1051309C (zh) 2000-04-12
IL106176A (en) 2001-01-11
DK0577082T3 (da) 1996-05-06
DE69333339D1 (de) 2004-01-22
NO932371D0 (no) 1993-06-29
EP0577083B1 (en) 2003-12-10
CY1931A (en) 1997-05-16
PL174374B1 (pl) 1998-07-31
FI933017A0 (fi) 1993-06-30
FI933017A (fi) 1994-01-02
ATE256115T1 (de) 2003-12-15
HK155896A (en) 1996-08-23
JPH06179666A (ja) 1994-06-28
EP0577082A1 (en) 1994-01-05
GR3019635T3 (en) 1996-07-31
DE69302137D1 (de) 1996-05-15
ATE136460T1 (de) 1996-04-15
HU220666B1 (hu) 2002-04-29
CN1082541A (zh) 1994-02-23
ES2211861T3 (es) 2004-07-16
IL106176A0 (en) 1993-10-20
EP0577082B1 (en) 1996-04-10
NZ248017A (en) 1994-12-22
AU656475B2 (en) 1995-02-02
JP3261550B2 (ja) 2002-03-04
MX9303900A (es) 1995-01-31
HU9301902D0 (en) 1993-09-28
AU4155693A (en) 1994-01-06
FI110942B (fi) 2003-04-30
NO302520B1 (no) 1998-03-16
PL299513A1 (en) 1994-03-07
HUT64529A (en) 1994-01-28
NO932371L (no) 1994-01-03
DE69302137T2 (de) 1996-11-14
DE69333339T2 (de) 2004-09-23
EP0577083A1 (en) 1994-01-05

Similar Documents

Publication Publication Date Title
DE69331892T2 (de) Desoxy-Taxol-Derivate
ATE195939T1 (de) 6,7-veränderte paclitaxele
CA2099232A1 (en) Fluoro taxols
ES2087616T3 (es) Fluoro-taxoles con actividad anti-tumoral.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 0577082

Country of ref document: ES